Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors
摘要:
A series of benzotriazole phenyldifluoromethylphosphonic acids were found to be potent PTP-1B inhibitors. Molecular modeling on the X-ray crystal structure of the lead structure led to the design of potent PTP-1B inhibitors that show moderate selectivity against TC-PTP, a very closely related protein tyrosine phosphatase. (C) 2004 Elsevier Ltd. All rights reserved.
DOI:
10.1016/j.bmcl.2003.11.076
作为产物:
描述:
alkaline earth salt of/the/ methylsulfuric acid 生成 6,8-二溴-2-甲基喹啉
参考文献:
名称:
Lawson; Perkin; Robinson, Journal of the Chemical Society, 1924, vol. 125, p. 653
Synthesis of quinolines and naphthyridines via catalytic retro-aldol reaction of β-hydroxyketones with ortho-aminobenzaldehydes or nicotinaldehydes
作者:Song-Lin Zhang、Zhu-Qin Deng
DOI:10.1039/c6ob01452f
日期:——
Cu(I)-catalyzed retro-aldol reaction of β-hydroxyketones with ortho-aminobenzaldehydes and nicotinaldehydes is reported that produces a range of quinolines and naphthyridines with high efficiency and selectivity. This reaction uses β-hydroxyketones as a regiospecific ketone-protected enolate source viacopper-catalyzed retro-aldol Cα–Cβ bond cleavage. The in situ generated copper enolate undergoes kinetically
Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
申请人:——
公开号:US20020052346A1
公开(公告)日:2002-05-02
The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme.
1
The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related conditions.
Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
申请人:——
公开号:US20020091104A1
公开(公告)日:2002-07-11
The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme.
1
The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes.